NEW YORK, June 23, 2025 -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 (Ac-225), demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi® (enzalutamide) and is effective in Xtandi® resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto® therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.